Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity

Journal of the Neurological Sciences

Volumn 331, Issue 1-2, 2013, Pages 38-42

  Szalardy, Levente ^a   Zadori, Denes ^a   Simu, Mihaela ^b   Bencsik, Krisztina ^a   Vecsei, Laszlo ^a   Klivenyi, Peter ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Beta amyloid; Biomarkers; Cerebrospinal fluid; ELISA; Multiple sclerosis; Osteopontin; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; OSTEOPONTIN; TAU PROTEIN;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; T LYMPHOCYTE;

EID: 84882453644     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.04.024     Document Type: Article

References (41)

1. Gajofatto A, Bongianni M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci 2011;12:7960-70.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46: 907-11.
3. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-12.
4. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002;59:1668-80.
5. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43:228-32.
6. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261-5.
7. Valis M, Talab R, Stourac P, Andrys C, Masopust J. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. Neuro Endocrinol Lett 2008;29:971-6.
8. Hein Nee Maier K, Kohler A, Diem R, Sattler MB, Demmer I, Lange P, et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 2008;436:72-6.
9. Mori F, Rossi S, Sancesario G, Codeca C, Mataluni G, Monteleone F, et al. Cognitive and cortical plasticity deficits correlate with altered amyloid-beta CSF levels in multiple sclerosis. Neuropsychopharmacology 2011;36:559-68.
10. Rostasy K, Withut E, Pohl D, Lange P, Ciesielcyk B, Diem R, et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol 2005;20:822-5.
11. Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 2008;65:633-5.
12. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009;16:528-36.
13. Bornsen L, Khademi M, Olsson T, Sorensen PS, Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011;17:32-42.
14. Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2012;244:94-6.
15. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis 2010;19: 1143-8.
16. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, et al. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 2007;25:473-82.
17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
18. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007;115:325-30.
19. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004;251:414-20.
20. Bartosik-Psujek H, Psujek M, Jaworski J, Stelmasiak Z. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand 2011;123:252-6.
21. Avsar T, Korkmaz D, Tutuncu M, Demirci NO, Saip S, Kamasak M, et al. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler 2012;18:1081-91.
22. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12:143-8.
23. Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, Medina-Acebron S, de Bustos F, Barcenilla B, et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002;106:351-4.
24. Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing- remitting multiple sclerosis. Neurosci Lett 2004;363:14-7.
25. Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006;12:354-6.
26. Fiorini M, Zanusso G, Benedetti MD, Righetti PG, Monaco S. Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics Clin Appl 2007;1:963-71.
27. Colucci M, Roccatagliata L, Capello E, Narciso E, Latronico N, Tabaton M, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler 2004;10:477-81.
28. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-9.
29. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:95-8.
30. Jaworski J, Psujek M, Janczarek M, Szczerbo-Trojanowska M, Bartosik-Psujek H. Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Ups J Med Sci 2012;117:284-92.
31. Anderson JM, Patani R, Reynolds R, Nicholas R, Compston A, Spillantini MG, et al. Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol 2010;119:591-600.
32. Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008;131: 1736-48.
33. Anderson JM, Patani R, Reynolds R, Nicholas R, Compston A, Spillantini MG, et al. Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol 2009;117:583-9.
34. Schneider A, Araujo GW, Trajkovic K, Herrmann MM, Merkler D, Mandelkow EM, et al. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J Biol Chem 2004;279:55833-9.
35. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontininduced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007;8:74-83.
36. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-5.
37. JanssonM, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin- deficient mice. J Immunol 2002;168:2096-9.
38. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008;181:7480-8.
39. Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC, et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol 2009;39:2525-36.
40. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008;65:232-5.
41. Romme Christensen J, Bornsen L, KhademiM, Olsson T, Jensen PE, Sorensen PS, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2012, http://dx.doi.org/10.1177/ 1352458512466929 [Electronic publication ahead of print].